ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.106,16
-0,17%
S&P 500
5.649,61
0,33%
US Dollar vs BRL
5,4326
-0,29%
Bitcoin
64.974,71
0,19%
Brent Oil
83,43
-1,08%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH
DataHoraFonteTítuloCódigoCompanhia
21/12/201011:00Business WireAllos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/12/201011:00Business WireAllos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/12/201018:15Business WireNew Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/201012:00Business WireUpdated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201012:00Business WireNew Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis FungoidesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201012:00Business WireAllos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/12/201011:00Business WireAllos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/11/201011:00Business WireNew FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201018:10Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201018:05Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201018:00Business WireAllos Therapeutics Reports Third Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/10/201018:00Business WireAllos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/10/201019:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201011:06Dow Jones NewsAllos Granted Orphan Status In Europe For Lymphoma DrugNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201010:00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201009:19Dow Jones NewsAllos' Pralatrexate Outperforms Tarceva In Lung-Cancer StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201008:15Business WireAllos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/10/201011:00GlobeNewswire Inc.Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing BellNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/09/201017:14Edgar (US Regulatory)Amended Current report filing (8-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/09/201018:40Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/09/201010:00Business WireAllos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/09/201014:29Business WireAllos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO CongressNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/201018:50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/201017:19Edgar (US Regulatory)Amended Annual Report (10-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/07/201017:17Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201008:30Business WireAllos Therapeutics Reports Second Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201008:00Business WireAllos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/07/201010:00Business WireAllos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/06/201010:00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/06/201012:45Business WireAllos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
TELB4
TELEBRAS PN
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
AMER3
Americanas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
COGN3
COGNA ON
BOV
BOBR4
BOMBRIL PN
BOV
AMAR3
LOJAS MARISA ON
BOV
LUPA3
LUPATECH ON
BOV
TCSA3
TECNISA ON
BOV
PRIO3
PETRORIO ON
BOV
GOLL4
GOL PN
BOV
AGXY3
Agrogalaxy Participacoes ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados